SAGE Working Group on hepatitis B (November 2008 to September 2009)
Terms of Reference
To review the evidence with respect to the following questions/issues and to propose to SAGE recommendations, including the need to update recommendations stated in the current (2004) hepatitis B vaccine position paper.
- Review data regarding the optimal timing of the hepatitis B vaccine birth dose to prevent perinatal hepatitis B virus transmission.
- Review position paper recommendations regarding the hepatitis B vaccine birth dose and the need to modify or reemphasize the current strategy for prevention of perinatal hepatitis B virus transmission.
- Identify additional critical issues that need to be considered in updating, referencing and providing evidence grading for the current hepatitis B vaccine position paper.
- Review issues related to establishment of regional or global hepatitis B control goals.
- Outline aspects of a comprehensive strategy for hepatitis B control.
- Xiaofeng Liang, Chair
- Salah al-Awaidy (SAGE member until November 2008)
- Silvia Bino
- Georges Peter (SAGE member until November 2008)
- Rakesh Aggarwal, Department of Gastroenterology, Sanjay Gandhi Institute of Medical Sciences, India
- Peggy Chibuye, United States Agency for International Development (USAID), Malawi
- Andy Hall, London School of Hygiene and Tropical Medicine, United Kingdom
- Fernando de la Hoz, National Institute of Health, Colombia
- Nobuhiko Okabe, National Insitute of Infectious Diseases, Japan (resigned from Working Group)
- Pierre Van Damme, Chair of EURO ETAGE, Professor, Vaccine & Infectious Diseases Institute, University of Antwerp, Belgium
- John Ward, Centres of Disease Control and Prevention, USA
- Steven Wiersma
DECLARATION OF INTERESTS FOR WHO EXPERTS
All members completed a declaration of interest. Only 4 members reported any interests.
Dr Fernando de la Hoz
Dr de la Hoz reported that he had travel expenses paid by Wyeth for attendance at technical meetings and that his research group received funds from Sanofi Pasteur to conduct an assessment of malarial drugs effectiveness.
Dr Georges Peter
Dr Peter reported serving on the meningococcal Advisory Board for GlaxoSmithKline for which he receives a limited amount of consultancy fees. The last meeting was in 2006. Currently he serves on a Safety Monitoring Board involving post-licensure safety assessment for RotaTeqTM and earlier served on the DSMB for an investigational H5N1 vaccine and for which he has received a small financial compensation from Merck & Co Inc. and Novavax Inc. respectively.
Prof Andy Hall
Prof. Hall reported that he was reimbursed as a consultant to PATH for serving on a data safety monitoring board for conjugate meningococcal A vaccine trials.
Prof Pierre van Damme
Prof. van Damme reported that his employer, the University of Antwerp, receives research support from various vaccine manufacturers for the conduct of vaccine trials and educational grants for the organization of the Viral Hepatitis Prevention Board.
Last updated: 9 March 2009
Last updated: 9 March 2009